VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

VolitionRX Limited (NYSEAMERICAN:VNRX) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.81 and traded as low as $1.1550. VolitionRX shares last traded at $1.16, with a volume of 124,738 shares.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Benchmark restated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Maxim Group reissued a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research note on Thursday, June 18th. Citigroup lowered VolitionRX to a “hold” rating in a research note on Monday, April 20th. Finally, HC Wainwright dropped their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, VolitionRX currently has an average rating of “Hold” and a consensus price target of $28.00.

VolitionRX Trading Down 1.7%

The stock’s fifty day moving average price is $1.81 and its 200-day moving average price is $3.45. The firm has a market cap of $10.01 million, a price-to-earnings ratio of -0.28 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. Analysts predict that VolitionRX Limited will post -2.4 earnings per share for the current year.

Institutional Investors Weigh In On VolitionRX

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of VolitionRX in the 3rd quarter valued at $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRX in the 2nd quarter valued at about $52,000. Jane Street Group LLC purchased a new stake in VolitionRX in the 4th quarter valued at about $28,000. Squarepoint Ops LLC acquired a new position in VolitionRX in the fourth quarter valued at about $34,000. Finally, Citadel Advisors LLC boosted its stake in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.